|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Insomnia | |||||
| Generalized Anxiety Disorder | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Anxiety Disorders | |||||
| Disease | |||||
| Sleep Initiation and Maintenance Disorders | |||||
| 3 | More general conditions related to this trial | ||||
| Dyssomnias | |||||
| Mental Disorders | |||||
| Nervous System Diseases | |||||
| Pathologic Processes | |||||
| Sleep Disorders | |||||
| Sleep Disorders, Intrinsic | |||||
| 4 | Interventions listed in this trial | ||||
| Eszopiclone (Lunesta) | |||||
| 5 | Sponsors listed in this trial | ||||
| Sepracor, Inc. | |||||